Gregory Critchfield, MD, MS


Dr. Critchfield is the Chairman and CEO of CHV portfolio company Sera Prognostics and has had a 30+ year career as an executive in molecular diagnostics.  Prior to joining Sera, Greg was the President of Myriad Genetic Laboratories from 1998-2010, during which time Myriad launched seven novel molecular diagnostic tests and increased revenue from $2M to over $325M.  Prior to Myriad, Dr. Critchfield served as Senior Vice President/Chief Medical and Science Officer of Corning Clinical Labs/Quest Diagnostics.  He serves on the board of numerous diagnostic companies.  He holds B.S. in Microbiology from BYU, an M.D. from the University of Utah College of Medicine, and an M.S. in Biophysical Sciences from the University of Minnesota.